Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	121.99	177.7
Short-Term Investments	99.85	217.36
Cash & Cash Equivalents	221.84	395.05
Cash Growth	-43.85%	-
Receivables	-	0.31
Other Current Assets	12.53	12.13
Total Current Assets	234.37	407.49
Property, Plant & Equipment	29.15	37.69
Goodwill and Intangibles	59.86	63.38
Other Long-Term Assets	6.81	9.7
Total Long-Term Assets	95.82	110.77
Total Assets	330.18	518.26
Accounts Payable	3.84	5.67
Deferred Revenue	21.19	42.43
Current Debt	15.01	16.72
Other Current Liabilities	42.16	21.82
Total Current Liabilities	82.2	86.63
Long-Term Debt	53.52	60.26
Other Long-Term Liabilities	5.83	16.62
Total Long-Term Liabilities	59.35	76.87
Total Liabilities	141.55	163.5
Total Debt	68.53	76.97
Debt Growth	-10.97%	-
Retained Earnings	-676.29	-473.14
Comprehensive Income	0.11	0.12
Shareholders' Equity	-615.97	-434.52
Net Cash (Debt)	153.31	318.08
Net Cash (Debt) Growth	-51.80%	-
Working Capital	152.16	320.87

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).